These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
617 related articles for article (PubMed ID: 27694178)
21. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
22. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531 [TBL] [Abstract][Full Text] [Related]
25. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836 [TBL] [Abstract][Full Text] [Related]
26. Establishing Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332 [TBL] [Abstract][Full Text] [Related]
27. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951 [TBL] [Abstract][Full Text] [Related]
28. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Ceci F; Castellucci P; Fanti S Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482 [TBL] [Abstract][Full Text] [Related]
29. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving Seifert R; Seitzer K; Herrmann K; Kessel K; Schäfers M; Kleesiek J; Weckesser M; Boegemann M; Rahbar K Theranostics; 2020; 10(17):7812-7820. PubMed ID: 32685021 [No Abstract] [Full Text] [Related]
30. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747 [TBL] [Abstract][Full Text] [Related]
31. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006 [TBL] [Abstract][Full Text] [Related]
32. PSMA PET and Radionuclide Therapy in Prostate Cancer. Bouchelouche K; Turkbey B; Choyke PL Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432 [TBL] [Abstract][Full Text] [Related]
33. Preparation and Biological Evaluation of [ Xiao D; Duan X; Gan Q; Zhang X; Zhang J Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058 [TBL] [Abstract][Full Text] [Related]
34. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. Hofman MS; Iravani A PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455 [TBL] [Abstract][Full Text] [Related]
35. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. Miyahira AK; Pienta KJ; Morris MJ; Bander NH; Baum RP; Fendler WP; Goeckeler W; Gorin MA; Hennekes H; Pomper MG; Sartor O; Tagawa ST; Williams S; Soule HR Prostate; 2018 Aug; 78(11):775-789. PubMed ID: 29717499 [TBL] [Abstract][Full Text] [Related]
36. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective. Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083 [TBL] [Abstract][Full Text] [Related]
37. Current use of PSMA-PET in prostate cancer management. Maurer T; Eiber M; Schwaiger M; Gschwend JE Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337 [TBL] [Abstract][Full Text] [Related]
38. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands. Naik M; Khan SR; Lewington V; Challapalli A; Eccles A; Barwick TD Br J Radiol; 2024 Aug; 97(1160):1391-1404. PubMed ID: 38733571 [TBL] [Abstract][Full Text] [Related]
39. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Hofman MS; Hicks RJ; Maurer T; Eiber M Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333 [TBL] [Abstract][Full Text] [Related]